Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Venous Thromboembolism and Membranous Nephropathy: So What's New?

Jai Radhakrishnan
CJASN January 2012, 7 (1) 3-4; DOI: https://doi.org/10.2215/CJN.11791111
Jai Radhakrishnan
Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jr55@columbia.edu
  • Article
  • Info & Metrics
  • View PDF
Loading

The association of venous thromboembolism (VTE) with the nephrotic syndrome, particularly deep vein and renal vein thrombosis (DVT and RVT, respectively) is firmly established (1–3). In a retrospective study of 298 nephrotic patients followed for a mean period of 10 years (4), the annual incidence of VTE was 1.02%/yr, and the absolute risk of arterial thrombosis was 1.48%/yr. The risk of both venous and arterial thrombosis was particularly high within the first 6 months of diagnosis (with annual incidences of 9.85% and 5.52%, respectively) (4). In children with the nephrotic syndrome, 9.2% of 326 patients experienced 38 thromboembolic episodes over a median period of 3.7 years (5). This risk is particularly high in patients with idiopathic membranous nephropathy.

Deep vein thrombosis (DVT) of the lower extremities is the most commonly observed site of thrombosis. In review of hospital discharges from 1979 to 2005, of 925,000 patients with a diagnosis of nephrotic syndrome, 14,000 (1.5%) were diagnosed with DVT; <5000 had RVT (6). Pulmonary embolism (PE) has been previously described in nephrotic patients with or without an evident DVT or RVT (1,7). In a study of 89 nephrotic patients with a serum albumin <2.0 g/dl (20 g/L), 19 (21%) patients had a high probability V/Q scan, and, in patients with low or intermediate probability scans, pulmonary angiograms demonstrated PE in another 10 patients (8,9). The renal vein is a classic site for thrombosis in nephrotic patients, being unusual in healthy subjects, and the prevalence of RVT can vary from 22% to 52% (2,7,10). Acute RVT is uncommon, with chronic RVT being predominant. Chronic RVT is insidious, usually discovered incidentally or when a workup for the source of pulmonary embolism reveals it. Although it has been suggested that a chronic RVT may lead to worsening proteinuria or kidney function, this has never been clearly documented (10). In a single case report of a patient with unilateral RVT and nephrotic syndrome due to membranous nephropathy, bilateral ureteral catheterization studies showed no difference in protein excretion or creatinine clearance between the two kidneys (11).

The reason(s) underlying the hypercoagulable state in nephrotic patients are not clearly understood. There is evidence of ongoing subclinical coagulation using measures of hemostasis activation, such as the plasma level of fibrinopeptide A (9) and D-dimer. Multiple hemostatic abnormalities have been described, including decreased levels of antithrombin and plasminogen (due to urinary losses), increased platelet activation, hyperfibrinogenemia, inhibition of plasminogen activation, and the presence of high-molecular-weight circulating fibrinogen moieties (9). The possibility of immune complex injury in the glomerulus resulting in systemic effects on clotting has also been evoked (9).

The risk of thrombosis seems to be related to the severity and duration of the nephrotic state and seems to be particularly increased with serum albumin concentrations ≤2.0 g/dl (20 g/L) (9). Furthermore, among the causes of nephrotic syndrome, the risk is highest with membranous nephropathy, followed by membranoproliferative GN and minimal change disease (9).

The diagnosis of thrombotic complications is usually based on clinical suspicion and confirmed by the appropriate imaging study (CT angiogram, nuclear scans, and ultrasound/Doppler scans). Whether asymptomatic patients should be screened is not clear because there is an absence of studies that show clinical benefit from screening. Besides, if there is an initially negative study, patients could conceivably develop thrombosis at a later stage.

The role of prophylactic anticoagulation (especially in patients with membranous nephropathy with severe nephrosis) has been debated (12). Using Markov modeling, Sarasin and Schifferli (13) have calculated that the mortality benefit of prophylactic anticoagulation outweighs the risk. In the authors’ opinion, prophylactic anticoagulation is suggested in patients with massive proteinuria, a serum albumin <2.0 g/dl (20 g/L), and an additional risk factor for thrombosis (e.g., a prior idiopathic thromboembolic event; immobilization; severe heart failure; morbid obesity; or abdominal, orthopedic, or gynecologic surgery). Patients who achieve remission of nephrotic syndrome should have anticoagulation discontinued 6 months after remission if there is no other indication for anticoagulation (9).

In the article by Lionaki et al in this issue of CJASN (14), the largest ever reported cohort (n=898) of patients with membranous nephropathy was analyzed for the incidence of thromboembolic events and predisposing factors contributing to this risk. The main messages from this paper were the relatively low(er) risk for VTE of 7.2% compared with some earlier studies, the fact that most episodes occur within the first 2 years (median time, 3.8 months from diagnosis of nephrosis), and the serum albumin supersedes urinary protein with respect to risk. This retrospectively studied cohort of adult patients was assembled from two North American tertiary care centers with large populations of glomerular patients and represented only idiopathic membranous nephropathy. There were some baseline differences in the two cohorts reflecting the populations and practices of the respective institutions. About one-half of the patients were on antiplatelet agents at the time of VTE (suggesting that these agents might not provide protection). The good news is that VTE did not adversely affect renal survival, and no patient died as a consequence of VTE (actual patient survival data with and without VTE are not shown).

In this study, the diagnosis of VTE was made with the appropriate scanning technique, which was performed when there was a clinical suspicion (i.e., routine screening was not performed). This likely led to the lower incidence of VTE (7.2%) compared with previous studies where RVT could be seen in up to 50% of patients and pulmonary emboli in 22% of patients who underwent prospective screening. However, there are no randomized trials looking at whether prospective screening leads to a better outcome.

The authors report that the risk of VTE begins at a threshold albumin of 2.8 g/dl and becomes higher as the albumin levels drop further. What was surprising was that VTE appeared early in the course of disease and was not related to the duration of hypoalbuminemia but to the level of serum albumin. This implies that there are as-yet unidentified patient-specific factors that, in addition to low albumin levels, confer the VTE risk.

There are several strengths to this study. The major strength of the study is that this is the largest such cohort assembled as a consequence of collaboration between two major institutions in North America—The Glomerular Disease Collaborative Networks (from the University of North Carolina, Chapel Hill, NC) and the Toronto Glomerulonephritis Registry (from the University of Toronto, Toronto, Canada). The authors have done an admirable job in collecting and analyzing VTE episodes and risk factors in a diverse group of patients. The VTE rate of 7%–8% was remarkably similar in the two cohorts, supporting the validity of their results. However, there are several limitations to the study. This study being of retrospective design, it is possible that all cases of VTE were not captured and that all risk factors were not systematically investigated. For example, likely due to small sample sizes (and possible under-reporting), protection from antiplatelet agents and risk from malignancies and smoking do not seem to be significant factors. Furthermore, recurrent VTE rates and response to anticoagulation are not mentioned. It is surprising that RVT was the predominant form of VTE (because these are clinically silent in the majority), which suggests that both clinical diagnosis and screening were used to define the patients with VTE (only 10 patients had VTE in at least one site).

In summary, although not much novel information is provided in the paper by Lionaki et al., due to the large sample size, it does serve to provide a better estimate and time of diagnosis of clinically manifest VTE events in patients with idiopathic membranous nephropathy. The serum albumin levels appear to be the pre-eminent risk factor. However, the single most important question in these patients is whether to anticoagulate prophylactically or not, and disappointingly, this was not addressed by the paper (but the authors promise this decision analysis is underway!).

Disclosures

None.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Venous Thromboembolism in Patients with Membranous Nephropathy,” on pages 43–51.

  • Copyright © 2012 by the American Society of Nephrology

References

  1. ↵
    1. Llach F
    : Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 28: 429–439, 1985
    OpenUrlPubMed
  2. ↵
    1. Singhal R,
    2. Brimble KS
    : Thromboembolic complications in the nephrotic syndrome: Pathophysiology and clinical management. Thromb Res 118: 397–407, 2006
    OpenUrlCrossRefPubMed
  3. ↵
    1. Crew RJ,
    2. Radhakrishnan J,
    3. Appel G
    : Complications of the nephrotic syndrome and their treatment. Clin Nephrol 62: 245–259, 2004
    OpenUrlPubMed
  4. ↵
    1. Mahmoodi BK,
    2. ten Kate MK,
    3. Waanders F,
    4. Veeger NJ,
    5. Brouwer JL,
    6. Vogt L,
    7. Navis G,
    8. van der Meer J
    : High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: Results from a large retrospective cohort study. Circulation 117: 224–230, 2008
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Kerlin BA,
    2. Blatt NB,
    3. Fuh B,
    4. Zhao S,
    5. Lehman A,
    6. Blanchong C,
    7. Mahan JD,
    8. Smoyer WE
    : Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: A Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr 155: 105–110, 110, e1, 2009
    OpenUrlCrossRefPubMed
  6. ↵
    1. Kayali F,
    2. Najjar R,
    3. Aswad F,
    4. Matta F,
    5. Stein PD
    : Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med 121: 226–230, 2008
    OpenUrlCrossRefPubMed
  7. ↵
    1. Llach F,
    2. Papper S,
    3. Massry SG
    : The clinical spectrum of renal vein thrombosis: Acute and chronic. Am J Med 69: 819–827, 1980
    OpenUrlPubMed
  8. ↵
    1. Cherng SC,
    2. Huang WS,
    3. Wang YF,
    4. Yang SP,
    5. Lin YF
    : The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism. Clin Nucl Med 25: 167–172, 2000
    OpenUrlCrossRefPubMed
  9. ↵
    1. Radhakrishnan J
    : Renal vein thrombosis and hypercoagulable state in nephrotic syndrome. In: UpToDate, edited by Sheridan AM, Waltham, MA, UpToDate, 2011
  10. ↵
    1. Wagoner RD,
    2. Stanson AW,
    3. Holley KE,
    4. Winter CS
    : Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: incidence and significance. Kidney Int 23: 368–374, 1983
    OpenUrlCrossRefPubMed
  11. ↵
    1. Kauffmann RH,
    2. de Graeff J,
    3. de la Rivière GB,
    4. van Es LA
    : Unilateral renal vein thrombosis and nephrotic syndrome. Report of a case with protein selectivity and antithrombin III clearance studies. Am J Med 60: 1048–1054, 1976
    OpenUrlCrossRefPubMed
  12. ↵
    1. Glassock RJ
    : Prophylactic anticoagulation in nephrotic syndrome: A clinical conundrum. J Am Soc Nephrol 18: 2221–2225, 2007
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Sarasin FP,
    2. Schifferli JA
    : Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 45: 578–585, 1994
    OpenUrlCrossRefPubMed
  14. ↵
    1. Lionaki S,
    2. Derebail V,
    3. Hogan SL,
    4. Barbour S,
    5. Lee T,
    6. Hladunewich M,
    7. Greenwald A,
    8. Hu Y,
    9. Jennette CE,
    10. Jennette JC,
    11. Falk RJ,
    12. Cattran DC,
    13. Nachman PH,
    14. Reich HN
    : Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 7: 43–51, 2012
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 7 (1)
Clinical Journal of the American Society of Nephrology
Vol. 7, Issue 1
January 13, 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Venous Thromboembolism and Membranous Nephropathy: So What's New?
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Venous Thromboembolism and Membranous Nephropathy: So What's New?
Jai Radhakrishnan
CJASN Jan 2012, 7 (1) 3-4; DOI: 10.2215/CJN.11791111

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Venous Thromboembolism and Membranous Nephropathy: So What's New?
Jai Radhakrishnan
CJASN Jan 2012, 7 (1) 3-4; DOI: 10.2215/CJN.11791111
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Steroid Regimen for Children with Nephrotic Syndrome Relapse
  • Mind the Gap
  • Opportunities for Improvement in Quality of Care of PD-Related Peritonitis in Children
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Venous Thromboembolism in Patients with Membranous Nephropathy
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire